DeepMind releases AlphaGenome 2 for cell-specific DNA effects

Google DeepMind said on Nov. 11 that AlphaGenome 2 predicts how a DNA sequence and its variants affect one cell type or cell state at a time, instead of averaging across a tissue. The lab said the model, trained on more than 107 million individual cell profiles, identified 30 percent of causal variants in the TenK10K immune-cell set, compared with 16 percent for the prior model fine-tuned on single-cell data. It is available for non-commercial research through the AlphaGenome API, with a private preview for commercial research, and DeepMind says it is not validated for clinical or diagnostic use.